Assessing Blueprint Medicines: Insights From 16 Financial Analysts
Assessing Blueprint Medicines: Insights From 16 Financial Analysts
评估blueprint medicines: 16名财务分析师的见解
In the preceding three months, 16 analysts have released ratings for Blueprint Medicines (NASDAQ:BPMC), presenting a wide array of perspectives from bullish to bearish.
在过去的三个月中，有16位分析师发布了Blueprint Medicines（NASDAQ:BPMC）的评级，呈现出从看好到看淡各种观点。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
总结他们最近的评估，下表展示了过去30天内不断变化的情绪，并将其与之前的几个月进行了比较。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $115.5, a high estimate of $168.00, and a low estimate of $75.00. Marking an increase of 19.69%, the current average surpasses the previous average price target of $96.50.
由分析师分析得出的12个月目标价值反映了市场和投资者对于股价的看法，平均目标价值为115.5美元，最高预估为168.00美元，最低预估为75.00美元。当前平均目标价值比之前的96.50美元提高了19.69%。
Analyzing Analyst Ratings: A Detailed Breakdown
分析分析师评级：详细剖析
A comprehensive examination of how financial experts perceive Blueprint Medicines is...
近期分析师的行动展示出...
登录免费看全文
登录/注册